← All countries · Americas
84%
MCV1
2025 · WHO/UNICEF estimate
84%
DTP3
2025 · WHO/UNICEF estimate
84%
IPV complete
2025 · WHO/UNICEF estimate
84%
HepB3
2025 · WHO/UNICEF estimate
5
Measles cases
2025 reported
4,633
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 87%2025 · WHO/UNICEF estimate | 95.7% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 92%2025 · WHO/UNICEF estimate | 94.9% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 84%2025 · WHO/UNICEF estimate | 89.9% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 91%2025 · WHO/UNICEF estimate | 95.1% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 84%2025 · WHO/UNICEF estimate | 89.8% | C · weak | |
| MCV1First dose of measles-containing vaccine | 84%2025 · WHO/UNICEF estimate | 90.5% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 66%2025 · WHO/UNICEF estimate | 82.1% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 84%2025 · WHO/UNICEF estimate | 90.5% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 84%2025 · WHO/UNICEF estimate | 89.9% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 83%2025 · WHO/UNICEF estimate | 91.0% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 84%2025 · WHO/UNICEF estimate | 89.9% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 96.6%2025 · Administrative (country-reported) | 96.6% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 80%2025 · WHO/UNICEF estimate | 88.8% | A · strong | |
| RotaCRotavirus vaccine, complete series | 87%2025 · WHO/UNICEF estimate | 92.9% | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | 61%2025 · WHO/UNICEF estimate | 79.8% | A · strong | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 97%2024 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 80%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 80%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 70%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 52025 | 0.1per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 3412025 | 9.9per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 4,6332025 | 134per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 162025 | 0.5per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 22025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | B · good | |
| Yellow fever all countries · vaccine evidence | 492025 | 1.4per 1,000,000 total population | A · strong | |
| Invasive meningococcal disease all countries · vaccine evidence | 72025 | 0.2per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02022 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (49 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DENGUEDengue vaccine | 1 | Y10-Y16 | Risk group(s) · SUBNATIONAL | esta vacuna, se aplica en distritos priorizados de 4 regiones del pais como vacuna de emergencia , por lo que no se encuentra dentro del esquema de rutina |
| DENGUEDengue vaccine | 2 | +M3 | Risk group(s) · SUBNATIONAL | esta vacuna, se aplica en distritos priorizados de 4 regiones del pais como vacuna de emergencia , por lo que no se encuentra dentro del esquema de rutina |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | M4 | Risk group(s) | aplicado cuando se tiene reaccion adversa a la 1era dosis vacuna pentavalente |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M6 | Risk group(s) | aplicado cuando se tiene reaccion adversa a la 1era dosis vacuna pentavalente |
| DTAPDTaP (acellular) vaccine | 1 | Y7 | General/routine | |
| DTAPDTaP (acellular) vaccine | 1 | Pregnant women | Gestantes entre las 20 a 36 semanas de gestación, DOSIS UNICA | |
| DTAPDTaP (acellular) vaccine | 2 | +M2 | Catch-up children | +M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario |
| DTAPDTaP (acellular) vaccine | 3 | +M6 | Catch-up children | +M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M15 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Y16 | Catch-up children | Población que no recibio el esquema primario |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Catch-up children | Población que no recibio el esquema primario |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Catch-up children | Población que no recibio el esquema primario |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | De acuerdo a la NTS 196-2022 MINSA-DGIESP vigente aprobada con RM 884-2022 MINSA / Recién nacidos dentro de las 12 horas de nacidos ideal y máximo dentro de las 24 horas. / Excepcional mente en partos domiciliarios se podrá vacunar hasta los 7 días de nacido |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | M4 | Risk group(s) | aplicado cuando se tiene reaccion adversa a la 1era dosis vacuna pentavalente |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M6 | Risk group(s) | aplicado cuando se tiene reaccion adversa a la 1era dosis vacuna pentavalente |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y18 | HPV administered to females and males | Se aplica dosis UNICA en mujeres y varones de 9 a 18 años |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M11 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | A partir del 2024 el esquema de antipolio es: 1 IPV, 2 IPV, 3 IPV, 1er Ref IPV, 2do Ref APO |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | A partir del 2024 el esquema de antipolio es: 1 IPV, 2 IPV, 3 IPV, 1er Ref IPV, 2do Ref APO |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | A partir del 2024 el esquema de antipolio es: 1 IPV, 2 IPV, 3 IPV, 1er Ref IPV, 2do Ref APO |
| IPVIPV (Inactivated polio vaccine) | 4 | M18 | General/routine | A partir del 2024 el esquema de antipolio es: 1 IPV, 2 IPV, 3 IPV, 1er Ref IPV, 2do Ref APO |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | |
| MPOXMpox (monkeypox) vaccine | 1 | >=Y18 | Risk group(s) | Población de grupos de riesgo priorizados, pre exposicion, post exposicion. Esta vacuna, se aplica en el pais como vacuna de emergencia , por lo que no se encuentra dentro del esquema de rutina |
| MPOXMpox (monkeypox) vaccine | 2 | +D28 | Risk group(s) | Población de grupos de riesgo priorizados, pre exposicion, post exposicion. Esta vacuna, se aplica en el pais como vacuna de emergencia , por lo que no se encuentra dentro del esquema de rutina |
| OPVOPV (Oral polio vaccine) | 5 | Y4 | General/routine | A partir del 2024 el esquema de antipolio es 2do Ref APO |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | >Y60 | Adults | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M12 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | M15 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.